NCT05536349View on ClinicalTrials.gov

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

PHASE2RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

April 25, 2028

Study Completion Date

April 25, 2028

Conditions

Leukemia

Interventions

DRUG

Pirtobrutinib

Given by PO

DRUG

Obinutuzumab

Given by (IV) vein

DRUG

Venetoclax

Given by PO

DRUG

Valacyclovir

Given by PO

DRUG

Allopurinol

Given by PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

collaborator

The Leukemia and Lymphoma Society

OTHER

lead

M.D. Anderson Cancer Center

OTHER